Other studies used certain small cell-penetrating peptides (CPPs) to inhibit NF-κB activation in animal models of different disorders, e.g., diabetes mellitus type 1 [65], inflammation (acute and chronic) [12, 66–68], and cancer [69, 70]. Here, NFKB1 is linked to diabetes mellitus.